Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Societal costs of illegal drug use in Sweden

Hofmarcher, Thomas LU ; Leppänen, Anne ; Månsdotter, Anna ; Strandberg, Joakim and Håkansson, Anders LU (2024) In International Journal of Drug Policy 123.
Abstract

Background: Illegal drug use is a public health concern with far-reaching consequences for people who use them and for society. In Sweden, the reported use of illegal drugs has been growing and the number of drug-induced deaths is among the highest in Europe. The aim of this study was to provide a comprehensive and up-to-date estimation of the societal costs of illegal drug use in Sweden, relying as much as possible on registry and administrative data. Methods: A prevalence-based cost-of-illness study of illegal drug use in Sweden in 2020 was conducted. A societal approach was chosen and included direct costs (such as costs of health care, social services, and the criminal justice system), indirect costs (such as lost productivity due... (More)

Background: Illegal drug use is a public health concern with far-reaching consequences for people who use them and for society. In Sweden, the reported use of illegal drugs has been growing and the number of drug-induced deaths is among the highest in Europe. The aim of this study was to provide a comprehensive and up-to-date estimation of the societal costs of illegal drug use in Sweden, relying as much as possible on registry and administrative data. Methods: A prevalence-based cost-of-illness study of illegal drug use in Sweden in 2020 was conducted. A societal approach was chosen and included direct costs (such as costs of health care, social services, and the criminal justice system), indirect costs (such as lost productivity due to unemployment and drug-induced death), and intangible costs (such as reduced quality of life among people who use drugs and their family members). Costs were estimated by combining registry, administrative, and survey data with unit cost data. Results: The estimated societal costs of illegal drug use were 3.7 billion euros in 2020. This corresponded to 355 euros per capita and 0.78 % of the gross domestic product. The direct and intangible costs were of similar sizes, each contributing to approximately 40 % of total costs, whereas indirect costs contributed to approximately 20 %. The largest individual cost components were reduced quality of life among people who use drugs and costs of the criminal justice system. Conclusion: Illegal drug use has a negative impact on the societal aim to create good and equitable health in Sweden. The findings call for evidence-based prevention of drug use and treatment for those addicted. It is important to address the co-morbidity of mental ill-health and drug dependence, to develop low-threshold services and measures for early prevention among children and young adults, as well as to evaluate laws and regulations connected to illegal drug use.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cost-of-illness, Economic burden, Illegal drugs, Illicit drugs, Societal costs, Substance use disorder
in
International Journal of Drug Policy
volume
123
article number
104259
publisher
Elsevier
external identifiers
  • pmid:38035447
  • scopus:85178475925
ISSN
0955-3959
DOI
10.1016/j.drugpo.2023.104259
language
English
LU publication?
yes
id
9d2d636c-20e1-46c1-a7cb-a19b58284867
date added to LUP
2023-12-18 15:18:58
date last changed
2024-04-17 03:31:18
@article{9d2d636c-20e1-46c1-a7cb-a19b58284867,
  abstract     = {{<p>Background: Illegal drug use is a public health concern with far-reaching consequences for people who use them and for society. In Sweden, the reported use of illegal drugs has been growing and the number of drug-induced deaths is among the highest in Europe. The aim of this study was to provide a comprehensive and up-to-date estimation of the societal costs of illegal drug use in Sweden, relying as much as possible on registry and administrative data. Methods: A prevalence-based cost-of-illness study of illegal drug use in Sweden in 2020 was conducted. A societal approach was chosen and included direct costs (such as costs of health care, social services, and the criminal justice system), indirect costs (such as lost productivity due to unemployment and drug-induced death), and intangible costs (such as reduced quality of life among people who use drugs and their family members). Costs were estimated by combining registry, administrative, and survey data with unit cost data. Results: The estimated societal costs of illegal drug use were 3.7 billion euros in 2020. This corresponded to 355 euros per capita and 0.78 % of the gross domestic product. The direct and intangible costs were of similar sizes, each contributing to approximately 40 % of total costs, whereas indirect costs contributed to approximately 20 %. The largest individual cost components were reduced quality of life among people who use drugs and costs of the criminal justice system. Conclusion: Illegal drug use has a negative impact on the societal aim to create good and equitable health in Sweden. The findings call for evidence-based prevention of drug use and treatment for those addicted. It is important to address the co-morbidity of mental ill-health and drug dependence, to develop low-threshold services and measures for early prevention among children and young adults, as well as to evaluate laws and regulations connected to illegal drug use.</p>}},
  author       = {{Hofmarcher, Thomas and Leppänen, Anne and Månsdotter, Anna and Strandberg, Joakim and Håkansson, Anders}},
  issn         = {{0955-3959}},
  keywords     = {{Cost-of-illness; Economic burden; Illegal drugs; Illicit drugs; Societal costs; Substance use disorder}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{International Journal of Drug Policy}},
  title        = {{Societal costs of illegal drug use in Sweden}},
  url          = {{http://dx.doi.org/10.1016/j.drugpo.2023.104259}},
  doi          = {{10.1016/j.drugpo.2023.104259}},
  volume       = {{123}},
  year         = {{2024}},
}